Skip to main content

FDA Approvals

Payers' Guide, FDA Approvals
Imbruvica (Ibrutinib) Now FDA Approved as First-Line Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide, FDA Approvals
Lartruvo (Olaratumab) a Novel First-Line Treatment Approved for Patients with Advanced Soft-Tissue Sarcoma
Loretta Fala
Read More
Payers' Guide, FDA Approvals
Revlimid (Lenalidomide) Receives New Indication for Multiple Myeloma as Maintenance Therapy After Transplantation
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide, FDA Approvals
Rubraca (Rucaparib) Second PARP Inhibitor Approved for Patients with Advanced, BRCA-Positive Ovarian Cancer
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide, FDA Approvals
Soliqua 100/33 (Insulin Glargine plus Lixisenatide) Receives FDA Approval for Adults with Type 2 Diabetes
Loretta Fala
Read More
Payers' Guide, FDA Approvals
Sustol (Granisetron) First Extended-Release 5-HT3 Receptor Antagonist Approved for the Prevention of Acute and Delayed CINV
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide, FDA Approvals
Xeljanz XR (Tofacitinib) First Once-Daily Oral JAK Inhibitor Approved for Patients with Rheumatoid Arthritis
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Innovation Continues to Drive Drug Development, Even as FDA Approvals Drop in 2016
Dalia Buffery, MA, ABD
Read More
FDA Approvals
Novel Hypomethylating Agent Active in Patients with High-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Charles Bankhead
Read More
FDA Approvals
Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in AML or High-Risk MDS
Wayne Kuznar
Read More
Page 33 of 53
Results 321 - 330 of 528